Ubs Group Ag Silence Therapeutics PLC Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Ubs Group Ag holds 70,661 shares of SLN stock, worth $447,990. This represents 0.0% of its overall portfolio holdings.

Number of Shares

70,661

Previous 73,806 4.26%

Holding current value

$447,990

Previous $1.4 Million 8.35%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$15.53 - $21.74 $48,841 - $68,372	-3,145 Reduced 4.26%	70,661 $1.29 Million
Q2 2024 Aug 13, 2024	BUY	$18.31 - $23.91 $34,569 - $45,142	1,888 Added 2.63%	73,806 $1.4 Million
Q1 2024 May 13, 2024	BUY	$17.39 - $26.25 $34,293 - $51,765	1,972 Added 2.82%	71,918 $1.55 Million
Q4 2023 Feb 09, 2024	BUY	$6.7 - $17.67 $5,581 - $14,719	833 Added 1.21%	69,946 $1.21 Million
Q3 2023 Nov 09, 2023	SELL	$5.07 - $10.74 $5,156 - $10,922	-1,017 Reduced 1.45%	69,113 $678,000
Q2 2023 Aug 11, 2023	BUY	$4.61 - $7.44 $5,181 - $8,362	1,124 Added 1.63%	70,130 $385,000
Q4 2022 Feb 08, 2023	BUY	$9.69 - $17.09 $30,920 - $54,534	3,191 Added 4.85%	69,006 $1.05 Million
Q3 2022 Nov 10, 2022	SELL	$2.65 - $29.85 $9,116 - $102,684	-3,440 Reduced 4.97%	65,815 $660,000
Q2 2022 Aug 10, 2022	SELL	$7.99 - $19.5 $902 - $2,203	-113 Reduced 0.16%	69,255 $821,000
Q1 2022 May 16, 2022	SELL	$16.5 - $23.89 $14,025 - $20,306	-850 Reduced 1.21%	69,368 $1.32 Million
Q4 2021 Feb 14, 2022	BUY	$20.61 - $25.71 $1.45 Million - $1.81 Million	70,218 New	70,218 $1.68 Million
Q1 2021 May 12, 2021	SELL	$21.8 - $28.01 $2,027 - $2,604	-93 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$15.0 - $22.0 $1,395 - $2,046	93 New	93 $2,000

Others Institutions Holding SLN

# of Institutions

Shares Held

28.1M

Call Options Held

300

Put Options Held

View Full List

About Silence Therapeutics plc

Ticker SLN
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,888,400
Market Cap $228M
Description
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...

More about SLN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account